バイオ医薬品受託製造市場レポート：2025-2035

Biopharmaceuticals Contract Manufacturing Market Report 2025-2035

概要バイオ医薬品受託製造市場レポート 2025-2035 (米国貿易関税の影響を含む）：本レポートは、新たな収益の柱を目指す大手企業にとって、業界とその根底にある力学をより深く理解する上で貴重なも... もっと見る

出版社	出版年月	電子版価格	納期	ページ数	言語
Visiongain ヴィジョンゲイン社	2025年9月1日	GBP5,150 部署ライセンスライセンス・価格情報注文方法はこちら	2営業日程度	393	英語

※上記価格は部署ライセンス（Departmental licence）価格です。
その他の価格についてはデータリソースまでお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

目次
図表リスト

サマリー

概要

バイオ医薬品受託製造市場レポート 2025-2035(米国貿易関税の影響を含む）：本レポートは、新たな収益の柱を目指す大手企業にとって、業界とその根底にある力学をより深く理解する上で貴重なものとなろう。異業種への進出や、新たな地域での既存事業の拡大を目指す企業にとっても有用なレポートです。

バイオ医薬品受託製造は、複雑な生物製剤や先端療法を扱う企業にとって重要な手段となっている。モノクローナル抗体、細胞治療、遺伝子治療の需要が高まる中、アウトソーシングは、バイオ医薬品の革新的企業に、スケーラブルで規制に準拠したインフラへのアクセスを提供すると同時に、探索と開発にリソースを集中させることを可能にする。製造受託機関（CMO）は、市場投入までの時間を短縮し、コストを最適化し、多くの企業が社内で再現できない技術的専門知識を提供する上で、極めて重要な役割を果たしている。

この分野は、がん、希少疾患、自己免疫疾患に対応する治療薬のパイプラインの拡大に後押しされ、力強い成長を遂げている。また、ブロックバスターとなる生物製剤の特許切れが開発・製造提携の波に拍車をかける中、バイオシミラーも重要な推進力となっている。新興のバイオテクノロジー企業も世界的な製薬企業も、業務の敏捷性と資本効率を高めるためにCMOを利用するようになっている。COVID-19のパンデミックは、レジリエントで大容量のネットワークの重要性をさらに浮き彫りにし、CMOを世界的なヘルスケア対策における不可欠なパートナーとして確固たるものにした。

AIを活用したプロセスの最適化から連続バイオプロセスまで、技術の進歩は外部委託生産における効率と品質基準を変革しつつある。同時に、インドや中国などの新興市場は、コスト競争力と規制枠組みの改善に支えられ、グローバル・サプライチェーンに不可欠な存在になりつつある。こうした動きは、受託製造の地理的な足跡を拡大し、リスクを分散させ、新たな成長の道を開いている。

生物製剤や次世代治療薬の需要が加速する中、製造受託はバイオ医薬品のバリューチェーンの要であり続ける。CMOは、キャパシティ・プロバイダーから戦略的パートナーへと進化を遂げ、競争と変化の激しいグローバル・ヘルスケアの現場でますます不可欠となる革新性、回復力、柔軟性を提供している。

米国の貿易関税が世界のバイオ医薬品受託製造市場に与える影響とは？

医薬品原料、生物製剤、特殊な製造装置に対する米国の貿易関税の導入は、世界のバイオ医薬品受託製造市場に新たな圧力をもたらしている。原材料、試薬、重要な製造ツールのコストを引き上げることで、これらの措置は確立されたコスト構造とサプライチェーンを破壊している。国境を越えた調達や米国への輸出に依存している受託製造業者は、営業コストの上昇、潜在的な遅延、利幅の減少に直面し、特に危険にさらされている。このような要因は、スポンサーの価格上昇につながり、生物製剤やバイオシミラーの値ごろ感を制限する可能性がある。

同時に、関税はグローバルなアウトソーシング戦略の見直しを促している。バイオ医薬品企業は、サプライヤーの多様化、現地生産能力への投資、関税の影響を受けない地域へのアウトソーシングを進めている。このシフトにより、東南アジア、インド、一部の欧州市場への関心が高まっており、規制基準の改善と競争力のあるコスト基盤が事業拡大を後押ししている。米国を拠点とするCMOは、短期的には内需拡大の恩恵を受けるかもしれないが、このポジションを維持できるかどうかは、政策の明確化とインフラ投資の規模にかかっている。

事実上、関税はディスラプター（破壊者）であると同時にカタリスト（触媒）として作用している。CMOとそのパートナーにとっては、短期的な課題と、より弾力的で地域的に多様な供給ネットワークを構築する長期的な機会とのバランスをとりながら、迅速に適応することが優先される。

市場調査レポートを購入する前にすべき質問とは？

バイオ医薬品受託製造市場はどのように進化しているのか？
何がバイオ医薬品受託製造市場を促進し、抑制しているのか？
バイオ医薬品受託製造の各サブマーケットは予測期間中にどのように成長し、2035年にはどれくらいの売上高を占めるようになるのか？
2025年から2035年にかけて、各バイオ医薬品受託製造サブマーケットの市場シェアはどのように推移するのか？
2025年から2035年にかけて、市場全体を牽引する主な要因は何か？
主要なバイオ医薬品受託製造市場は、マクロ経済の動きに幅広く追随するのだろうか、それとも個々の国の市場が他を凌駕するのだろうか？
2035年までに各国市場のシェアはどのように変化し、どの地域が2035年の市場をリードするのか。
主要プレーヤーと予測期間中の見通しは？
これらの大手企業のバイオ医薬品受託製造プロジェクトとは？
2025年から2035年にかけて、業界はどのように進化するのか？その影響は？
バイオ医薬品受託製造プロジェクトが現在、そして今後10年の間に行われるのか？
バイオ医薬品受託製造市場をさらに拡大するために、製品の商業化の必要性は高まっているのでしょうか？
バイオ医薬品受託製造市場はどこに向かっているのか、また、どのようにして市場の最前線に立つことができるのか。
新商品や新サービスに最適な投資方法とは？
企業を新たな成長軌道に乗せ、C-suiteに移行させるための重要な展望とは？

バイオ医薬品受託製造市場が現在、そして今後10年間でどのような影響を受けるかを知る必要がある：

393ページに及ぶレポートには、138の表と174の図表が掲載されている。
本レポートでは、業界における主要な有利分野を取り上げているため、今すぐターゲットを絞ることができる。
世界、地域、国の売上高と成長に関する詳細な分析が含まれている。
競合他社が成功した主なトレンド、変化、収益予測をハイライトします。

2035年までの予測やその他の分析から、商業的な展望が見えてきた

2035年までの収益予測に加え、最新の実績、成長率、市場シェアも提供する。
ビジネスの展望や展開など、独自の分析が掲載されている。
定性的分析（市場ダイナミクス、促進要因、機会、阻害要因など）、ポーターのファイブフォース分析、PEST分析、最近の動向をご覧いただけます。

レポート対象セグメント

ソース

哺乳類
非哺乳類

サービス

プロセス開発
– 下流工程
– 上流工程
フィル＆フィニッシュオペレーション
分析＆QCスタディ
パッケージング

製品

生物製剤
– モノクローナル抗体（mAb）
– 組換えタンパク質
– ワクチン
– その他
バイオシミラー

会社規模

小型
中型
大型

事業規模

前臨床試験
臨床
商業

治療分野

腫瘍学
自己免疫疾患
心血管疾患
代謝性疾患
感染症
神経学
その他

世界市場全体と各分野の売上予測に加え、5つの地域と26の主要国市場の売上予測も掲載しています：

北米

米国
カナダ

欧州

ドイツ
英国
フランス
イタリア
スペイン
その他の欧州地域

アジア太平洋

日本
中国
インド
オーストラリア
韓国
その他のアジア太平洋地域

ラテンアメリカ

ブラジル
メキシコ
その他のラテンアメリカ地域

MEA

GCC
南アフリカ
その他のMEA地域

バイオ医薬品受託製造市場レポート 2025-2035

本レポートでは、バイオ医薬品受託製造市場の2025年から2035年にかけての主要企業のプロファイルも掲載しており、これらの企業の事業のこのセグメントに焦点を当てている。

主要企業と市場成長の可能性

AbbVie Inc.
AGC Biologics
Avantor, Inc.
Binex Co., Ltd.
Boehringer Ingelheim International GmbH
Cambrex Corporation
Catalent, Inc
Curia Global, Inc.
Cytiva
FUJIFILM Diosynth Biotechnologies
JRS PHARMA
Jubilant Pharma Limited
KBI Biopharma
Lonza
Pfizer CentreOne
ProBioGen AG
Rentschler Biopharma SE
Samsung Biologics
Sandoz Group AG
TOYOBO CO., LTD.
Thermo Fisher Scientific Inc.
WuXi Biologics

2025年から2035年までのバイオ医薬品受託製造市場全体の世界売上高（金額ベース）は、2025年に170億米ドルを突破する。2035年まで売上は力強く成長すると予測している。当社の調査では、最も大きな可能性を秘めた企業を特定しています。彼らの能力、進歩、商業的見通しを発見し、あなたが一歩先を行くのを支援します。

バイオ医薬品受託製造市場、2025-2035年レポートはどのようにお役に立ちますか？

要約すると、390ページを超えるこのレポートは、以下の知識を提供する：

バイオ医薬品受託製造市場の2025年から2035年までの収益予測、供給元、サービス、製品、企業規模、事業規模の各予測を世界レベルと地域レベルで掲載 - 業界の将来性を発見し、投資と収益に最も有利な場所を見つけることができます。
5つの地域と26の主要国市場の2035年までの収益予測 - 北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、MEAのバイオ医薬品受託製造市場の2025年から2035年までの予測をご覧ください。また、米国、カナダ、メキシコ、ブラジル、ドイツ、フランス、英国、イタリア、中国、インド、日本、オーストラリアなどの主要国の市場も予測しています。
2025年から2035年までのバイオ医薬品受託製造市場に関わる主要企業22社の企業プロファイルを含む。

独自の予測による定量的・定性的分析をご覧ください。私たちのレポートだけに含まれる情報を入手し、貴重なビジネスインテリジェンスで情報を入手しましょう。

ページTOPに戻る

1 レポート概要
1.1 研究の目的
1.2 バイオ医薬品受託製造市場の紹介
1.3 本レポートの内容
1.4 本レポートを読むべき理由
1.5 本分析レポートが回答する主な質問は以下の通り：
1.6 本レポートの対象者
1.7 方法論
1.7.1 市場の定義
1.7.2 市場評価・予測手法
1.7.3 データの検証
1.7.3.1 一次調査
1.7.3.2 セカンダリーリサーチ
1.8 よくある質問（FAQ）
1.9 Visiongainの関連レポート
1.10 Visiongainについて

2 エグゼクティブ・サマリー

3 市場概要
3.1 主要な調査結果
3.2 市場ダイナミクス
3.3 影響分析
3.3.1 市場促進要因
3.3.1.1 CMOによる生産能力拡大のための投資の増加
3.3.1.2 コントラクトサービスが提供するコストと時間の節約効果
3.3.1.3 市場成長を後押しするアウトソーシング
3.3.1.4 希少医薬品への投資の増加
3.3.2 市場抑制要因
3.3.2.1 市場成長を阻害する価格圧力
3.3.2.2 厳しい規制シナリオ
3.3.2.3 過剰生産能力による市場成長の阻害要因
3.3.3 市場機会
3.3.3.1 フィル＆フィニッシュCMOの拡大
3.3.3.2 シングルユースバイオプロセシング機器・ソリューションの出現
3.3.3.3 新興国は有利な成長機会を提供する
3.4 米国の関税：世界のバイオ医薬品受託製造市場への影響は？
3.4.1 概要
3.4.2 V字回復シナリオ
3.4.3 なぜV字回復なのか？
3.4.3.1 関税による影響
3.4.3.2 市場ダイナミクスと需要回復
3.4.3.3 政策と資金援助
3.4.3.4 回復のタイムフレーム
3.4.4 U字型回復シナリオ
3.4.4.1 なぜU字型回復なのか？
3.4.4.2 関税による影響
3.4.4.3 市場ダイナミクスと需要回復
3.4.4.4 政策と資金援助
3.4.4.5 回復のタイムフレーム
3.4.5 L字型回復シナリオ
3.4.5.1 なぜL字型回復なのか？
3.4.5.2 関税による影響
3.4.5.3 市場ダイナミクスと需要回復
3.4.5.4 政策と資金援助
3.4.5.5 回復のタイムフレーム
3.4.6 顧客が短期（2025-2030年）および長期（2025-2035年）計画に織り込むべき戦略的考慮事項とは？
3.4.7 米中貿易戦争がバイオ医薬品受託製造市場に与える影響
3.4.8 最も影響を受ける国は、これらの政策変更によってどのようなプラス効果とマイナス効果を経験するか？
3.5 ポーターのファイブフォース分析
3.5.1 買い手の交渉力
3.5.2 サプライヤーの交渉力
3.5.3 競争上のライバル関係
3.5.4 代替品の脅威
3.5.5 新規参入企業の脅威
3.6 PEST分析
3.6.1 バイオ医薬品受託製造市場に影響を与える政治的要因
3.6.2 バイオ医薬品受託製造市場に影響を与える経済的要因
3.6.3 バイオ医薬品受託製造市場に影響を与える社会的要因
3.6.4 バイオ医薬品受託製造市場に影響を与える技術的要因

4 バイオ医薬品受託製造市場分析：ソース別
4.1 主要な調査結果
4.2 ソース・セグメント市場魅力度指数
4.3 バイオ医薬品受託製造の供給源別市場規模推定と予測
4.4 哺乳類
4.4.1 2025〜2035年の地域別市場予測（百万米ドル、AGR）
4.4.2 地域別市場シェア、2025年＆2035年(%)
4.5 哺乳類以外
4.5.1 2025〜2035年の地域別市場予測（百万米ドル、AGR）
4.5.2 地域別市場シェア、2025年＆2035年(%)

5 バイオ医薬品受託製造市場分析：サービス別
5.1 主要な調査結果
5.2 サービスセグメント市場魅力度指数
5.3 バイオ医薬品受託製造のサービス別市場規模推定と予測
5.4 プロセス開発
5.4.1 タイプ別プロセス開発市場規模推定と予測
5.4.2 上流プロセス開発
5.4.3 下流プロセス開発
5.4.4 2025-2035年地域別市場予測（百万米ドル、AGR）
5.4.5 地域別市場シェア、2025年＆2035年(%)
5.5 充填・仕上げ作業
5.5.1 2025～2035年の地域別市場展望（百万米ドル、AGR）
5.5.2 地域別市場シェア、2025年＆2035年(%)
5.6 分析・QC業務
5.6.1 2025〜2035年の地域別市場予測（百万米ドル、AGR）
5.6.2 地域別市場シェア、2025年＆2035年(%)
5.7 パッケージング
5.7.1 2025〜2035年の地域別市場予測（百万米ドル、AGR）
5.7.2 地域別市場シェア、2025年＆2035年(%)

6 バイオ医薬品受託製造市場分析：製品別
6.1 主要な調査結果
6.2 製品セグメント市場魅力度指数
6.3 バイオ医薬品受託製造の製品別市場規模推定と予測
6.4 生物製剤
6.4.1 2025〜2035年の地域別市場予測（百万米ドル、AGR）
6.4.2 地域別市場シェア、2025年＆2035年(%)
6.4.3 生物製剤のタイプ別市場規模推定と予測
6.4.3.1 モノクローナル抗体（mAbs）
6.4.3.2 組換えタンパク質
6.4.3.3 ワクチン
6.4.3.4 その他
6.5 バイオシミラー
6.5.1 2025-2035年地域別市場予測（百万米ドル、AGR）
6.5.2 地域別市場シェア、2025年＆2035年(%)

7 バイオ医薬品受託製造市場分析：企業規模別
7.1 主要な調査結果
7.2 企業規模セグメント市場魅力度指数
7.3 企業規模別バイオ医薬品受託製造市場規模推定と予測
7.4 小型
7.4.1 2025〜2035年地域別市場予測（百万米ドル、AGR）
7.4.2 地域別市場シェア、2025年＆2035年(%)
7.5 中型
7.5.1 2025-2035年地域別市場予測（百万米ドル、AGR）
7.5.2 地域別市場シェア、2025年＆2035年(%)
7.6 大型
7.6.1 2025-2035年地域別市場展望（百万米ドル、AGR）
7.6.2 地域別市場シェア、2025年＆2035年(%)

8 バイオ医薬品受託製造市場分析：事業規模別
8.1 主要な調査結果
8.2 事業規模セグメント市場魅力度指数
8.3 バイオ医薬品受託製造の事業規模別市場規模の推定と予測
8.4 前臨床
8.4.1 2025〜2035年の地域別市場予測（百万米ドル、AGR）
8.4.2 地域別市場シェア、2025年＆2035年(%)
8.5 臨床試験
8.5.1 2025〜2035年の地域別市場展望（百万米ドル、AGR）
8.5.2 地域別市場シェア、2025年＆2035年(%)
8.6 商業
8.6.1 2025〜2035年の地域別市場展望（百万米ドル、AGR）
8.6.2 地域別市場シェア、2025年＆2035年(%)

9 バイオ医薬品受託製造市場分析：治療領域別
9.1 主要な調査結果
9.2 治療領域セグメント市場魅力度指数
9.3 バイオ医薬品受託製造の治療領域別市場規模の推定と予測
9.4 オンコロジー
9.4.1 2025〜2035年の地域別市場予測（百万米ドル、AGR）
9.4.2 地域別市場シェア、2025年＆2035年(%)
9.5 自己免疫疾患
9.5.1 2025〜2035年の地域別市場予測（百万米ドル、AGR）
9.5.2 地域別市場シェア、2025年＆2035年(%)
9.6 循環器疾患
9.6.1 2025〜2035年の地域別市場予測（百万米ドル、AGR）
9.6.2 地域別市場シェア、2025年＆2035年(%)
9.7 代謝性疾患
9.7.1 2025〜2035年の地域別市場予測（百万米ドル、AGR）
9.7.2 地域別市場シェア、2025年＆2035年(%)
9.8 感染症
9.8.1 2025〜2035年の地域別市場予測（百万米ドル、AGR）
9.8.2 地域別市場シェア、2025年＆2035年(%)
9.9 神経
9.9.1 2025〜2035年の地域別市場展望（百万米ドル、AGR）
9.9.2 地域別市場シェア、2025年＆2035年(%)
9.10 その他
9.10.1 2025〜2035年の地域別市場予測（百万米ドル、AGR）
9.10.2 地域別市場シェア、2025年＆2035年(%)

10 バイオ医薬品受託製造市場分析：地域別
10.1 主要な調査結果
10.2 地域別市場規模の推定と予測

11 北米のバイオ医薬品受託製造市場分析
11.1 主要な調査結果
11.2 北米のバイオ医薬品受託製造市場魅力度指数
11.3 北米のバイオ医薬品受託製造市場の国別市場規模、2025年、2030年、2035年（百万米ドル）
11.4 北米のバイオ医薬品受託製造国別市場規模推定と予測
11.5 北米のバイオ医薬品受託製造市場規模推定と予測：ソース別
11.6 北米のバイオ医薬品受託製造市場規模推定と予測：サービス別
11.7 北米のバイオ医薬品受託製造市場規模推定と予測：製品別
11.8 北米のバイオ医薬品受託製造市場規模推定と予測：企業規模別
11.9 北米のバイオ医薬品受託製造市場規模推定と予測：事業規模別
11.10 北米のバイオ医薬品受託製造市場規模推定と予測：治療分野別
11.11 米国のバイオ医薬品受託製造市場分析
11.12 カナダのバイオ医薬品受託製造市場分析

12 欧州のバイオ医薬品受託製造市場分析
12.1 主要な調査結果
12.2 欧州のバイオ医薬品受託製造市場魅力度指数
12.3 欧州のバイオ医薬品受託製造市場の国別推移、2025年、2030年、2035年（百万米ドル）
12.4 欧州のバイオ医薬品受託製造国別市場規模推定と予測
12.5 欧州のバイオ医薬品受託製造市場規模推定と予測：ソース別
12.6 欧州のバイオ医薬品受託製造市場規模推定と予測：サービス別
12.7 欧州のバイオ医薬品受託製造市場規模推定と予測：製品別
12.8 欧州のバイオ医薬品受託製造市場規模推定と予測：企業規模別
12.9 欧州のバイオ医薬品受託製造市場規模推定と予測：事業規模別
12.10 欧州のバイオ医薬品受託製造市場規模推定と予測：治療領域別
12.11 ドイツのバイオ医薬品受託製造市場分析
12.12 英国のバイオ医薬品受託製造市場分析
12.13 フランスのバイオ医薬品受託製造市場分析
12.14 イタリアのバイオ医薬品受託製造市場分析
12.15 スペインのバイオ医薬品受託製造市場分析
12.16 ロシアのバイオ医薬品受託製造市場分析
12.17 オランダのバイオ医薬品受託製造市場分析
12.18 スイスのバイオ医薬品受託製造市場分析
12.19 その他の欧州のバイオ医薬品受託製造市場分析

13 アジア太平洋地域のバイオ医薬品受託製造市場分析
13.1 主要な調査結果
13.2 アジア太平洋地域のバイオ医薬品受託製造市場魅力度指数
13.3 アジア太平洋地域のバイオ医薬品受託製造市場の国別市場規模、2025年、2030年、2035年（百万米ドル）
13.4 アジア太平洋地域のバイオ医薬品受託製造国別市場規模推定と予測
13.5 アジア太平洋地域のバイオ医薬品受託製造市場規模推定と予測：ソース別
13.6 アジア太平洋地域のバイオ医薬品受託製造市場規模推定と予測：サービス別
13.7 アジア太平洋地域のバイオ医薬品受託製造市場規模推定と予測：製品別
13.8 アジア太平洋地域のバイオ医薬品受託製造市場規模推定と予測：企業規模別
13.9 アジア太平洋地域のバイオ医薬品受託製造市場規模推定と予測：事業規模別
13.10 アジア太平洋地域のバイオ医薬品受託製造市場規模推定と予測：治療分野別
13.11 日本のバイオ医薬品受託製造市場分析
13.12 中国のバイオ医薬品受託製造市場分析
13.13 インドの生物医薬品受託製造市場分析
13.14 オーストラリアのバイオ医薬品受託製造市場分析
13.15 韓国のバイオ医薬品受託製造市場分析
13.16 東南アジアのバイオ医薬品受託製造市場分析
13.17 その他のアジア太平洋地域のバイオ医薬品受託製造市場分析

14 ラテンアメリカのバイオ医薬品受託製造市場分析
14.1 主要な調査結果
14.2 ラテンアメリカのバイオ医薬品受託製造市場魅力度指数
14.3 ラテンアメリカのバイオ医薬品受託製造市場の国別市場規模、2025年、2030年、2035年（百万米ドル）
14.4 ラテンアメリカのバイオ医薬品受託製造の国別市場規模推定と予測
14.5 ラテンアメリカのバイオ医薬品受託製造市場規模推定と予測：ソース別
14.6 ラテンアメリカのバイオ医薬品受託製造市場規模推定と予測：サービス別
14.7 ラテンアメリカのバイオ医薬品受託製造市場規模推定と予測：製品別
14.8 ラテンアメリカのバイオ医薬品受託製造市場規模推定と予測：企業規模別
14.9 ラテンアメリカのバイオ医薬品受託製造市場規模推定と予測：事業規模別
14.10 ラテンアメリカのバイオ医薬品受託製造市場規模推定と予測：治療分野別
14.11 ブラジルのバイオ医薬品受託製造市場分析
14.12 メキシコ生物医薬品受託製造市場分析
14.13 アルゼンチンの生物医薬品受託製造市場分析
14.14 コロンビアの生物医薬品受託製造市場分析
14.15 その他のラテンアメリカの生物医薬品受託製造市場分析

15 MEAの

バイオ医薬品受託製造市場分析
15.1 主要な調査結果
15.2 MEAのバイオ医薬品受託製造市場魅力度指数
15.3 MEAのバイオ医薬品受託製造市場の国別市場規模、2025年、2030年、2035年（百万米ドル）
15.4 MEAのバイオ医薬品受託製造国別市場規模推定と予測
15.5 MEAのバイオ医薬品受託製造市場規模推定と予測：ソース別
15.6 MEAのバイオ医薬品受託製造市場規模推定と予測：サービス別
15.7 MEAのバイオ医薬品受託製造市場規模推定と予測：製品別
15.8 MEAのバイオ医薬品受託製造市場規模推定と予測：企業規模別
15.9 MEAのバイオ医薬品受託製造市場規模推定と予測：事業規模別
15.10 MEAのバイオ医薬品受託製造市場規模推定と予測：治療分野別
15.11 GCCのバイオ医薬品受託製造市場分析
15.12 南アフリカのバイオ医薬品受託製造市場分析
15.13 その他のMEAの生物医薬品受託製造市場分析

16 会社概要
16.1 アッヴィ社
16.1.1 会社概要
16.1.2 会社概要
16.1.3 財務分析
16.1.3.1 純収入、2020-2024年
16.1.3.2 研究開発費、2020-2024年
16.1.3.3 地域別市場シェア（2024年
16.1.3.4 事業セグメント市場シェア（2024年
16.1.4 サービスのベンチマーク
16.2 AGCバイオロジクス
16.2.1 会社概要
16.2.2 会社概要
16.2.3 サービス・ベンチマーク
16.2.4 戦略的展望
16.3 Avantor, Inc.
16.3.1 会社概要
16.3.2 会社概要
16.3.3 財務分析
16.3.3.1 純収入、2020-2024年
16.3.3.2 事業セグメント市場シェア、2024年
16.3.4 サービス・ベンチマーク
16.3.5 戦略的展望
16.4 株式会社バイネックス
16.4.1 会社概要
16.4.2 会社概要
16.4.3 サービスベンチマーク
16.5 ベーリンガーインゲルハイムGmbH
16.5.1 会社概要
16.5.2 会社概要
16.5.3 財務分析
16.5.3.1 純収入、2020-2024年
16.5.4 サービスベンチマーク
16.6 富士フイルムジオシンスバイオテクノロジーズ
16.6.1 会社概要
16.6.2 会社概要
16.6.3 サービス・ベンチマーク
16.6.4 戦略的展望
16.7 ロンザ
16.7.1 会社概要
16.7.2 会社概要
16.7.3 財務分析
16.7.3.1 純収入、2020-2024年
16.7.3.2 研究開発費、2018-2022年
16.7.4 サービスベンチマーク
16.7.5 戦略的展望
16.8 プロバイオジェン
16.8.1 会社概要
16.8.2 会社概要
16.8.3 サービス・ベンチマーク
16.8.4 戦略的展望
16.9 レンシュラーバイオファーマSE
16.9.1 会社概要
16.9.2 会社概要
16.9.3 サービス・ベンチマーク
16.9.4 戦略的展望
16.10 サムスンバイオロジクス
16.10.1 会社概要
16.10.2 会社概要
16.10.3 サービス・ベンチマーク
16.10.4 戦略的展望
16.11 サンド
16.11.1 会社概要
16.11.2 会社概要
16.11.3 財務分析
16.11.3.1 純収入、2020-2024年
16.11.3.2 地域市場シェア、2024年
16.11.4 サービス・ベンチマーク
16.11.5 戦略的展望
16.12 東洋紡績株式会社
16.12.1 会社概要
16.12.2 会社概要
16.12.3 サービス・ベンチマーク
16.13 呉西生物製剤
16.13.1 会社概要
16.13.2 会社概要
16.13.3 財務分析
16.13.3.1 純収入、2020-2024年
16.13.3.2 地域市場シェア、2024年
16.13.3.3 事業セグメント市場シェア（2024年
16.13.4 サービス・ベンチマーク
16.13.5 戦略的展望
16.14 JRSファーマ
16.14.1 会社概要
16.14.2 会社概要
16.14.3 サービス・ベンチマーク
16.15 サーモフィッシャーサイエンティフィック
16.15.1 会社概要
16.15.2 会社概要
16.15.3 財務分析
16.15.3.1 純収入、2020-2024年
16.15.3.2 売上高、2020-2024年
16.15.3.3 地域市場シェア、2024年
16.15.3.4 事業セグメント市場シェア（2024年
16.15.4 サービスのベンチマーク
16.16 カンブレックス・コーポレーション
16.16.1 会社概要
16.16.2 会社概要
16.16.3 サービス・ベンチマーク
16.16.4 戦略的展望
16.17 キュリアグローバル
16.17.1 会社概要
16.17.2 会社概要
16.17.3 サービス・ベンチマーク
16.17.4 戦略的展望
16.18 ファイザー・センターワン
16.18.1 会社概要
16.18.2 会社概要
16.18.3 財務分析
16.18.3.1 純収入、2020-2024年
16.18.3.2 売上高、2020-2024年
16.18.3.3 地域市場シェア、2024年
16.18.3.4 事業セグメント市場シェア（2024年
16.18.4 サービスのベンチマーク
16.19 ジュビラン・ファーマ
16.19.1 会社概要
16.19.2 会社概要
16.19.3 サービス・ベンチマーク
16.20 キャタレント（ノボホールディングス）
16.20.1 会社概要
16.20.2 会社概要
16.20.3 財務分析
16.20.3.1 純収入、2020-2024年
16.20.4 サービス・ベンチマーク
16.20.5 戦略的展望
16.21 KBIバイオファーマ
16.21.1 会社概要
16.21.2 会社概要
16.21.3 サービス・ベンチマーク
16.21.4 戦略的展望
16.22 サイティバ
16.22.1 会社概要
16.22.2 会社概要
16.22.3 サービス・ベンチマーク
16.22.4 戦略的展望

17 結論と提言
17.1 ビジョンゲインの結語
17.2 市場プレイヤーへの提言

ページTOPに戻る

図表リスト

List of Tables
Table 1 Biopharmaceuticals Contract Manufacturing Market Snapshot, 2025 & 2035 (US$ million, CAGR %)
Table 2 Biopharmaceuticals Contract Manufacturing Market Forecast by Region, 2025-2035 (US$ Mn, AGR %, CAGR %): "V" Shaped Recovery
Table 3 Biopharmaceuticals Contract Manufacturing Market Forecast by Region, 2025-2035 (US$ Mn, AGR %, CAGR %): "U" Shaped Recovery
Table 4 Biopharmaceuticals Contract Manufacturing Market Forecast by Region, 2025-2035 (US$ Mn, AGR %, CAGR %): "L" Shaped Recovery
Table 5 Biopharmaceuticals Contract Manufacturing Market Forecast by Source, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 6 Mammalian Segment Market Forecast by Region, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 7 Non-mammalian Segment Market Forecast by Region, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 8 Biopharmaceuticals Contract Manufacturing Market Forecast by Service, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 9 Process Development Segment Market Forecast by Region, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 10 Fill & Finish Operations Segment Market Forecast by Region, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 11 Analytical & QC Studies Segment Market Forecast by Region, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 12 Packaging Segment Market Forecast by Region, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 13 Biopharmaceuticals Contract Manufacturing Market Forecast by Product, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 14 Biologics Segment Market Forecast by Region, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 15 Biopharmaceuticals Contract Manufacturing Market Forecast by Application, 2025-2035 (US$ mn, AGR%, CAGR%)
Table 16 Biosimilars Segment Market Forecast by Region, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 17 Biopharmaceuticals Contract Manufacturing Market Forecast by Company Size, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 18 Small Segment Market Forecast by Region, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 19 Mid-sized Segment Market Forecast by Region, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 20 Large Segment Market Forecast by Region, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 21 Biopharmaceuticals Contract Manufacturing Market Forecast by Scale of Operation, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 22 Preclinical Segment Market Forecast by Region, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 23 Clinical Segment Market Forecast by Region, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 24 Commercial Segment Market Forecast by Region, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 25 Biopharmaceuticals Contract Manufacturing Market Forecast by Therapeutic Area, 2025-2035 (US$ mn, AGR%, CAGR%)
Table 26 Oncology Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 27 Autoimmune Diseases Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 28 Cardiovascular Diseases Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 29 Metabolic Diseases Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 30 Infectious Diseases Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 31 Neurology Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 32 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 33 Biopharmaceuticals Contract Manufacturing Market Forecast by Region, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 34 North America Biopharmaceuticals Contract Manufacturing Market Forecast by Country, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 35 North America Biopharmaceuticals Contract Manufacturing Market Forecast by Source, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 36 North America Biopharmaceuticals Contract Manufacturing Market Forecast by Service, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 37 North America Biopharmaceuticals Contract Manufacturing Market Forecast by Product, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 38 North America Biopharmaceuticals Contract Manufacturing Market Forecast by Company Size, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 39 North America Biopharmaceuticals Contract Manufacturing Market Forecast by Scale of Operation, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 40 North America Biopharmaceuticals Contract Manufacturing Market Forecast by Therapeutic Area, 2025-2035 (US$ mn, AGR%, CAGR%)
Table 41 U.S. Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 42 Canada Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 43 Europe Biopharmaceuticals Contract Manufacturing Market Forecast by Country, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 44 Europe Biopharmaceuticals Contract Manufacturing Market Forecast by Source, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 45 Europe Biopharmaceuticals Contract Manufacturing Market Forecast by Service, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 46 Europe Biopharmaceuticals Contract Manufacturing Market Forecast by Product, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 47 Europe Biopharmaceuticals Contract Manufacturing Market Forecast by Company Size, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 48 Europe Biopharmaceuticals Contract Manufacturing Market Forecast by Scale of Operation, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 49 Europe Biopharmaceuticals Contract Manufacturing Market Forecast by Therapeutic Area, 2025-2035 (US$ mn, AGR%, CAGR%)
Table 50 Germany Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 51 UK Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 52 France Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 53 Italy Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 54 Spain Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 55 Russia Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 56 Netherlands Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 57 Switzerland Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 58 Rest of Europe Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 59 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Forecast by Country, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 60 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Forecast by Source, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 61 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Forecast by Service, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 62 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Forecast by Product, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 63 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Forecast by Company Size, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 64 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Forecast by Scale of Operation, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 65 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Forecast by Therapeutic Area, 2025-2035 (US$ mn, AGR%, CAGR%)
Table 66 Japan Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 67 China Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 68 India Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 69 Australia Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 70 South Korea Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 71 South-East Asia Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 72 Rest of Asia Pacific Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 73 Latin America Biopharmaceuticals Contract Manufacturing Market Forecast by Country, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 74 Latin America Biopharmaceuticals Contract Manufacturing Market Forecast by Source, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 75 Latin America Biopharmaceuticals Contract Manufacturing Market Forecast by Service, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 76 Latin America Biopharmaceuticals Contract Manufacturing Market Forecast by Product, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 77 Latin America Biopharmaceuticals Contract Manufacturing Market Forecast by Company Size, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 78 Latin America Biopharmaceuticals Contract Manufacturing Market Forecast by Scale of Operation, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 79 Latin America Biopharmaceuticals Contract Manufacturing Market Forecast by Therapeutic Area, 2025-2035 (US$ mn, AGR%, CAGR%)
Table 80 Brazil Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 81 Mexico Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 82 Argentina Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 83 Colombia Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 84 Rest of Latin America Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 85 MEA Biopharmaceuticals Contract Manufacturing Market Forecast by Country, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 86 MEA Biopharmaceuticals Contract Manufacturing Market Forecast by Source, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 87 MEA Biopharmaceuticals Contract Manufacturing Market Forecast by Service, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 88 MEA Biopharmaceuticals Contract Manufacturing Market Forecast by Product, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 89 MEA Biopharmaceuticals Contract Manufacturing Market Forecast by Company Size, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 90 MEA Biopharmaceuticals Contract Manufacturing Market Forecast by Scale of Operation, 2025-2035 (US$ Mn, AGR %, CAGR %)
Table 91 MEA Biopharmaceuticals Contract Manufacturing Market Forecast by Therapeutic Area, 2025-2035 (US$ mn, AGR%, CAGR%)
Table 92 GCC Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 93 South Africa Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 94 Rest of MEA Biopharmaceuticals Contract Manufacturing) Market Forecast, 2025-2035 (US$ Million, AGR %, CAGR %)
Table 95 AbbVie, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 AbbVie, Inc.: Service Benchmarking
Table 97 AGC Biologics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 98 AGC Biologics: Service Benchmarking
Table 99 AGC Biologics: Strategic Outlook
Table 100 Avantor, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 101 Avantor, Inc.: Service Benchmarking
Table 102 Avantor, Inc.: Strategic Outlook
Table 103 Binex Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 104 Binex Co., Ltd.: Service Benchmarking
Table 105 Boehringer Ingelheim GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 106 Boehringer Ingelheim GmbH: Service Benchmarking
Table 107 FUJIFILM Diosynth Biotechnologies: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 FUJIFILM Diosynth Biotechnologies: Service Benchmarking
Table 109 FUJIFILM Diosynth Biotechnologies: Strategic Outlook
Table 110 Lonza: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 111 Lonza: Service Benchmarking
Table 112 Lonza: Strategic Outlook
Table 113 ProBioGen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 114 ProBioGen: Service Benchmarking
Table 115 ProBioGen: Strategic Outlook
Table 116 Rentschler Biopharma SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 117 Rentschler Biopharma SE: Service Benchmarking
Table 118 Rentschler Biopharma SE: Strategic Outlook
Table 119 Samsung Biologics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 120 Samsung Biologics: Service Benchmarking
Table 121 Samsung Biologics: Strategic Outlook
Table 122 Sandoz: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 123 Sandoz: Service Benchmarking
Table 124 Sandoz: Strategic Outlook
Table 125 TOYOBO CO., LTD.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 126 TOYOBO CO., LTD.: Service Benchmarking
Table 127 WuXi Biologics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 128 WuXi Biologics: Service Benchmarking
Table 129 WuXi Biologics: Strategic Outlook
Table 130 JRS PHARMA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 131 JRS PHARMA: Service Benchmarking
Table 132 Thermo Fisher Scientific: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 133 Thermo Fisher Scientific: Service Benchmarking
Table 134 Cambrex Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 135 Cambrex Corporation: Service Benchmarking
Table 136 Cambrex Corporation: Strategic Outlook
Table 137 Curia Global, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 138 Curia Global, Inc.: Service Benchmarking
Table 139 Curia Global, Inc.: Strategic Outlook
Table 140 Pfizer CentreOne: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 141 Pfizer CentreOne: Service Benchmarking
Table 142 Jubilant Pharma Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 143 Jubilant Pharma Limited: Service Benchmarking
Table 144 Catalent, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 145 Catalent, Inc: Service Benchmarking
Table 146 Catalent, Inc: Strategic Outlook
Table 147 KBI Biopharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 148 KBI Biopharma: Service Benchmarking
Table 149 KBI Biopharma: Strategic Outlook
Table 150 Cytiva: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 151 Cytiva: Service Benchmarking
Table 152 Cytiva: Strategic Outlook

List of Figures
Figure 1 Biopharmaceuticals Contract Manufacturing Market Segmentation
Figure 2 Biopharmaceuticals Contract Manufacturing Market by Source: Market Attractiveness Index
Figure 3 Biopharmaceuticals Contract Manufacturing Market by Service: Market Attractiveness Index
Figure 4 Biopharmaceuticals Contract Manufacturing Market by Product: Market Attractiveness Index
Figure 5 Biopharmaceuticals Contract Manufacturing Market by Company Size: Market Attractiveness Index
Figure 6 Biopharmaceuticals Contract Manufacturing Market by Scale of Operations: Market Attractiveness Index
Figure 7 Biopharmaceuticals Contract Manufacturing Market by Therapeutic Area: Market Attractiveness Index
Figure 8 Biopharmaceuticals Contract Manufacturing Market Attractiveness Index by Region
Figure 9 Biopharmaceuticals Contract Manufacturing Market: Market Dynamics
Figure 10 Biopharmaceuticals Contract Manufacturing Market: Impact Analysis
Figure 11 Biopharmaceuticals Contract Manufacturing Market by Region, 2025-2035 (US$ Million, AGR %), Tariff Impact: V-Shaped Recovery Scenario
Figure 12 Biopharmaceuticals Contract Manufacturing Market by Region, 2025-2035 (US$ Million, AGR %), Tariff Impact: U-Shaped Recovery Scenario
Figure 13 Biopharmaceuticals Contract Manufacturing Market by Region, 2025-2035 (US$ Million, AGR %), Tariff Impact: L-Shaped Recovery Scenario
Figure 14 Short Term & Long Term Planning
Figure 15 Impact of U.S. and China Trade War
Figure 16 Most Impacted Countries
Figure 17 SWOT Analysis
Figure 18 Porter’s Five Forces Analysis
Figure 19 PEST Analysis
Figure 20 Biopharmaceuticals Contract Manufacturing Market Attractiveness Index by Source
Figure 21 Biopharmaceuticals Contract Manufacturing Market Forecast by Source, 2025-2035 (US$ Million, AGR %)
Figure 22 Biopharmaceuticals Contract Manufacturing Market Share Forecast by Source, 2025, 2030 & 2035 (%)
Figure 23 Mammalian Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 24 Mammalian Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 25 Non-mammalian Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 26 Non-mammalian Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 27 Biopharmaceuticals Contract Manufacturing Market Attractiveness Index by Source
Figure 28 Biopharmaceuticals Contract Manufacturing Market Forecast by Service, 2025-2035 (US$ Million, AGR %)
Figure 29 Biopharmaceuticals Contract Manufacturing Market Share Forecast by Service, 2025, 2030 & 2035 (%)
Figure 30 Process Development Market Forecast by Type, 2025-2035 (US$ Million, AGR %)
Figure 31 Process Development Market by Type, 2025, 2030 & 2035 (%)
Figure 32 Process Development Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 33 Process Development Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 34 Fill & Finish Operations Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 35 Fill & Finish Operations Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 36 Analytical & QC Studies Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 37 Analytical & QC Studies Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 38 Packaging Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 39 Packaging Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 40 Biopharmaceuticals Contract Manufacturing Market Attractiveness Index by Product
Figure 41 Biopharmaceuticals Contract Manufacturing Market Forecast by Product, 2025-2035 (US$ Million, AGR %)
Figure 42 Biopharmaceuticals Contract Manufacturing Market Share Forecast by Product, 2025, 2030 & 2035 (%)
Figure 43 Biologics Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 44 Biologics Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 45 Biologics Market Forecast by Type, 2025-2035 (US$ Million, AGR %)
Figure 46 Biologics Market by Type, 2025, 2030 & 2035 (%)
Figure 47 Biosimilars Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 48 Biosimilars Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 49 Biopharmaceuticals Contract Manufacturing Market Attractiveness Index by Company Size
Figure 50 Biopharmaceuticals Contract Manufacturing Market Forecast by Company Size, 2025-2035 (US$ Million, AGR %)
Figure 51 Biopharmaceuticals Contract Manufacturing Market Share Forecast by Company Size, 2025, 2030 & 2035 (%)
Figure 52 Small Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 53 Small Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 54 Mid-sized Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 55 Mid-sized Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 56 Large Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 57 Large Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 58 Biopharmaceuticals Contract Manufacturing Market Attractiveness Index by Scale of Operations
Figure 59 Biopharmaceuticals Contract Manufacturing Market Forecast by Scale of Operations, 2025-2035 (US$ Million, AGR %)
Figure 60 Biopharmaceuticals Contract Manufacturing Market Share Forecast by Scale of Operations, 2025, 2030 & 2035 (%)
Figure 61 Preclinical Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 62 Preclinical Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 63 Clinical Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 64 Clinical Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 65 Commercial Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 66 Commercial Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 67 Biopharmaceuticals Contract Manufacturing Market Attractiveness Index by Therapeutic Area
Figure 68 Biopharmaceuticals Contract Manufacturing Market Forecast by Therapeutic Area, 2025-2035 (US$ Million, AGR %)
Figure 69 Biopharmaceuticals Contract Manufacturing Market Share Forecast by Therapeutic Area, 2025, 2030 & 2035 (%)
Figure 70 Oncology Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 71 Oncology Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 72 Autoimmune Diseases Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 73 Autoimmune Diseases Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 74 Cardiovascular Diseases Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 75 Cardiovascular Diseases Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 76 Metabolic Diseases Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 77 Metabolic Diseases Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 78 Infectious Diseases Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 79 Infectious Diseases Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 80 Neurology Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 81 Neurology Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 82 Others Segment Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
Figure 83 Others Segment Market Share Forecast by Region, 2025 & 2035 (%)
Figure 84 Biopharmaceuticals Contract Manufacturing Market Forecast by Region 2025, 2030 & 2035 (Revenue, CAGR%)
Figure 85 Biopharmaceuticals Contract Manufacturing Market Share Forecast by Region 2025, 2030 & 2035 (%)
Figure 86 Biopharmaceuticals Contract Manufacturing Market by Region, 2025-2035 (US$ Mn)
Figure 87 North America Biopharmaceuticals Contract Manufacturing Market Attractiveness Index
Figure 88 North America Biopharmaceuticals Contract Manufacturing Market by Region, 2025, 2030 & 2035 (US$ Million)
Figure 89 North America Biopharmaceuticals Contract Manufacturing Market Forecast by Country, 2025-2035 (US$ Million, AGR %)
Figure 90 North America Biopharmaceuticals Contract Manufacturing Market Share Forecast by Country, 2025 & 2035 (%)
Figure 91 North America Biopharmaceuticals Contract Manufacturing Market Forecast by Source, 2025-2035 (US$ Million, AGR %)
Figure 92 North America Biopharmaceuticals Contract Manufacturing Market Share Forecast by Source, 2025 & 2035 (%)
Figure 93 North America Biopharmaceuticals Contract Manufacturing Market Forecast by Service, 2025-2035 (US$ Million, AGR %)
Figure 94 North America Biopharmaceuticals Contract Manufacturing Market Share Forecast by Service, 2025 & 2035 (%)
Figure 95 North America Biopharmaceuticals Contract Manufacturing Market Forecast by Product, 2025-2035 (US$ Million, AGR %)
Figure 96 North America Biopharmaceuticals Contract Manufacturing Market Share Forecast by Product, 2025 & 2035 (%)
Figure 97 North America Biopharmaceuticals Contract Manufacturing Market Forecast by Company Size, 2025-2035 (US$ Million, AGR %)
Figure 98 North America Biopharmaceuticals Contract Manufacturing Market Share Forecast by Company Size, 2025 & 2035 (%)
Figure 99 North America Biopharmaceuticals Contract Manufacturing Market Forecast by Scale of Operations, 2025-2035 (US$ Million, AGR %)
Figure 100 North America Biopharmaceuticals Contract Manufacturing Market Share Forecast by Scale of Operations, 2025 & 2035 (%)
Figure 101 North America Biopharmaceuticals Contract Manufacturing Market Forecast by Therapeutic Area, 2025-2035 (US$ Million, AGR %)
Figure 102 North America Biopharmaceuticals Contract Manufacturing Market Share Forecast by Therapeutic Area, 2025 & 2035 (%)
Figure 103 U.S. Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 104 Canada Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 105 Europe Biopharmaceuticals Contract Manufacturing Market Attractiveness Index
Figure 106 Europe Biopharmaceuticals Contract Manufacturing Market by Region, 2025, 2030 & 2035 (US$ Million)
Figure 107 Europe Biopharmaceuticals Contract Manufacturing Market Forecast by Country, 2025-2035 (US$ Million, AGR %)
Figure 108 Europe Biopharmaceuticals Contract Manufacturing Market Share Forecast by Country, 2025 & 2035 (%)
Figure 109 Europe Biopharmaceuticals Contract Manufacturing Market Forecast by Source, 2025-2035 (US$ Million, AGR %)
Figure 110 Europe Biopharmaceuticals Contract Manufacturing Market Share Forecast by Source, 2025 & 2035 (%)
Figure 111 Europe Biopharmaceuticals Contract Manufacturing Market Forecast by Service, 2025-2035 (US$ Million, AGR %)
Figure 112 Europe Biopharmaceuticals Contract Manufacturing Market Share Forecast by Service, 2025 & 2035 (%)
Figure 113 Europe Biopharmaceuticals Contract Manufacturing Market Forecast by Product, 2025-2035 (US$ Million, AGR %)
Figure 114 Europe Biopharmaceuticals Contract Manufacturing Market Share Forecast by Product, 2025 & 2035 (%)
Figure 115 Europe Biopharmaceuticals Contract Manufacturing Market Forecast by Company Size, 2025-2035 (US$ Million, AGR %)
Figure 116 Europe Biopharmaceuticals Contract Manufacturing Market Share Forecast by Company Size, 2025 & 2035 (%)
Figure 117 Europe Biopharmaceuticals Contract Manufacturing Market Forecast by Scale of Operations, 2025-2035 (US$ Million, AGR %)
Figure 118 Europe Biopharmaceuticals Contract Manufacturing Market Share Forecast by Scale of Operations, 2025 & 2035 (%)
Figure 119 Europe Biopharmaceuticals Contract Manufacturing Market Forecast by Therapeutic Area, 2025-2035 (US$ Million, AGR %)
Figure 120 Europe Biopharmaceuticals Contract Manufacturing Market Share Forecast by Therapeutic Area, 2025 & 2035 (%)
Figure 121 Germany Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 122 UK Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 123 France Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 124 Italy Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 125 Spain Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 126 Russia Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 127 Netherlands Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 128 Switzerland Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 129 Rest of Europe Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 130 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Attractiveness Index
Figure 131 Asia Pacific Biopharmaceuticals Contract Manufacturing Market by Region, 2025, 2030 & 2035 (US$ Million)
Figure 132 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Forecast by Country, 2025-2035 (US$ Million, AGR %)
Figure 133 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Share Forecast by Country, 2025 & 2035 (%)
Figure 134 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Forecast by Source, 2025-2035 (US$ Million, AGR %)
Figure 135 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Share Forecast by Source, 2025 & 2035 (%)
Figure 136 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Forecast by Service, 2025-2035 (US$ Million, AGR %)
Figure 137 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Share Forecast by Service, 2025 & 2035 (%)
Figure 138 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Forecast by Product, 2025-2035 (US$ Million, AGR %)
Figure 139 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Share Forecast by Product, 2025 & 2035 (%)
Figure 140 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Forecast by Company Size, 2025-2035 (US$ Million, AGR %)
Figure 141 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Share Forecast by Company Size, 2025 & 2035 (%)
Figure 142 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Forecast by Scale of Operations, 2025-2035 (US$ Million, AGR %)
Figure 143 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Share Forecast by Scale of Operations, 2025 & 2035 (%)
Figure 144 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Forecast by Therapeutic Area, 2025-2035 (US$ Million, AGR %)
Figure 145 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Share Forecast by Therapeutic Area, 2025 & 2035 (%)
Figure 146 Japan Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 147 China Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 148 India Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 149 Australia Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 150 South Korea Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 151 South-East Asia Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 152 Rest of Asia Pacific Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 153 Latin America Biopharmaceuticals Contract Manufacturing Market Attractiveness Index
Figure 154 Latin America Biopharmaceuticals Contract Manufacturing Market by Region, 2025, 2030 & 2035 (US$ Million)
Figure 155 Latin America Biopharmaceuticals Contract Manufacturing Market Forecast by Country, 2025-2035 (US$ Million, AGR %)
Figure 156 Latin America Biopharmaceuticals Contract Manufacturing Market Share Forecast by Country, 2025 & 2035 (%)
Figure 157 Latin America Biopharmaceuticals Contract Manufacturing Market Forecast by Source, 2025-2035 (US$ Million, AGR %)
Figure 158 Latin America Biopharmaceuticals Contract Manufacturing Market Share Forecast by Source, 2025 & 2035 (%)
Figure 159 Latin America Biopharmaceuticals Contract Manufacturing Market Forecast by Service, 2025-2035 (US$ Million, AGR %)
Figure 160 Latin America Biopharmaceuticals Contract Manufacturing Market Share Forecast by Service, 2025 & 2035 (%)
Figure 161 Latin America Biopharmaceuticals Contract Manufacturing Market Forecast by Product, 2025-2035 (US$ Million, AGR %)
Figure 162 Latin America Biopharmaceuticals Contract Manufacturing Market Share Forecast by Product, 2025 & 2035 (%)
Figure 163 Latin America Biopharmaceuticals Contract Manufacturing Market Forecast by Company Size, 2025-2035 (US$ Million, AGR %)
Figure 164 Latin America Biopharmaceuticals Contract Manufacturing Market Share Forecast by Company Size, 2025 & 2035 (%)
Figure 165 Latin America Biopharmaceuticals Contract Manufacturing Market Forecast by Scale of Operations, 2025-2035 (US$ Million, AGR %)
Figure 166 Latin America Biopharmaceuticals Contract Manufacturing Market Share Forecast by Scale of Operations, 2025 & 2035 (%)
Figure 167 Latin America Biopharmaceuticals Contract Manufacturing Market Forecast by Therapeutic Area, 2025-2035 (US$ Million, AGR %)
Figure 168 Latin America Biopharmaceuticals Contract Manufacturing Market Share Forecast by Therapeutic Area, 2025 & 2035 (%)
Figure 169 Brazil Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 170 Mexico Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 171 Argentina Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 172 Colombia Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 173 Rest of Latin America Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 174 MEA Biopharmaceuticals Contract Manufacturing Market Attractiveness Index
Figure 175 MEA Biopharmaceuticals Contract Manufacturing Market by Region, 2025, 2030 & 2035 (US$ Million)
Figure 176 MEA Biopharmaceuticals Contract Manufacturing Market Forecast by Country, 2025-2035 (US$ Million, AGR %)
Figure 177 MEA Biopharmaceuticals Contract Manufacturing Market Share Forecast by Country, 2025 & 2035 (%)
Figure 178 MEA Biopharmaceuticals Contract Manufacturing Market Forecast by Source, 2025-2035 (US$ Million, AGR %)
Figure 179 MEA Biopharmaceuticals Contract Manufacturing Market Share Forecast by Source, 2025 & 2035 (%)
Figure 180 MEA Biopharmaceuticals Contract Manufacturing Market Forecast by Service, 2025-2035 (US$ Million, AGR %)
Figure 181 MEA Biopharmaceuticals Contract Manufacturing Market Share Forecast by Service, 2025 & 2035 (%)
Figure 182 MEA Biopharmaceuticals Contract Manufacturing Market Forecast by Product, 2025-2035 (US$ Million, AGR %)
Figure 183 MEA Biopharmaceuticals Contract Manufacturing Market Share Forecast by Product, 2025 & 2035 (%)
Figure 184 MEA Biopharmaceuticals Contract Manufacturing Market Forecast by Company Size, 2025-2035 (US$ Million, AGR %)
Figure 185 MEA Biopharmaceuticals Contract Manufacturing Market Share Forecast by Company Size, 2025 & 2035 (%)
Figure 186 MEA Biopharmaceuticals Contract Manufacturing Market Forecast by Scale of Operations, 2025-2035 (US$ Million, AGR %)
Figure 187 MEA Biopharmaceuticals Contract Manufacturing Market Share Forecast by Scale of Operations, 2025 & 2035 (%)
Figure 188 MEA Biopharmaceuticals Contract Manufacturing Market Forecast by Therapeutic Area, 2025-2035 (US$ Million, AGR %)
Figure 189 MEA Biopharmaceuticals Contract Manufacturing Market Share Forecast by Therapeutic Area, 2025 & 2035 (%)
Figure 190 GCC Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 191 South Africa Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 192 Rest of MEA Biopharmaceuticals Contract Manufacturing Market Forecast, 2025-2035 (US$ Million, AGR %)
Figure 193 AbbVie, Inc.: Net Revenue, 2020-2024 (US$ Million, AGR %)
Figure 194 AbbVie, Inc.: R&D Expenses, 2020-2024 (US$ Million, AGR %)
Figure 195 AbbVie, Inc.: Regional Market Shares, 2024(%)
Figure 196 AbbVie, Inc.: Business Segment Market Shares, 2024(%)
Figure 197 Avantor, Inc.: Net Revenue, 2020-2024 (US$ Million, AGR %)
Figure 198 Avantor, Inc.: Business Segment Market Share (%)
Figure 199 Boehringer Ingelheim GmbH: Net Revenue, 2020-2024 (US$ Million, AGR %)
Figure 200 Lonza: Net Revenue, 2020-2024 (US$ Million, AGR %)
Figure 201 Lonza: R&D Expenses, 2018-2022 (US$ Million, AGR %)
Figure 202 Sandoz: Net Revenue, 2020-2024 (US$ Million, AGR %)
Figure 203 Sandoz: Regional Market Share (%), 2024
Figure 204 WuXi Biologics: Net Revenue, 2020-2024 (US$ Million, AGR %)
Figure 205 WuXi Biologics: Regional Market Shares, 2024 (%)
Figure 206 WuXi Biologics: Business Segment Market Shares, 2024 (%)
Figure 207 Thermo Fisher Scientific: Net Revenue, 2020-2024 (US$ Million, AGR %)
Figure 208 Thermo Fisher Scientific: R&D, 2020-2024 (US$ Million, AGR %)
Figure 209 Thermo Fisher Scientific: Regional Market Shares, 2024 (%)
Figure 210 Thermo Fisher Scientific: Business Segment Market Shares, 2024 (%)
Figure 211 Pfizer CentreOne: Net Revenue, 2020-2024 (US$ Million, AGR %)
Figure 212 Pfizer CentreOne: R&D, 2020-2024 (US$ Million, AGR %)
Figure 213 Pfizer CentreOne: Regional Market Shares, 2024 (%)
Figure 214 Pfizer CentreOne: Business Segment Market Shares, 2024 (%)
Figure 215 Catalent, Inc: Net Revenue, 2020-2024 (US$ Million, AGR %)

ページTOPに戻る

Table of Contents
List of Tables/Graphs

Summary

Description

The Biopharmaceuticals Contract Manufacturing Market Report 2025-2035 (Including Impact of U.S. Trade Tariffs): This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Biopharmaceutical contract manufacturing has become a critical enabler for companies navigating the complexity of biologics and advanced therapies. With rising demand for monoclonal antibodies, cell therapies, and gene therapies, outsourcing provides biopharma innovators with access to scalable, regulatory-compliant infrastructure while allowing them to concentrate resources on discovery and development. Contract manufacturing organisations (CMOs) play a pivotal role in reducing time-to-market, optimising costs, and offering technical expertise that many firms cannot replicate in-house.

The sector is experiencing strong growth, propelled by the expanding pipeline of therapies addressing oncology, rare diseases, and autoimmune conditions. Biosimilars are also a key driver, as patent expirations on blockbuster biologics fuel a wave of development and manufacturing partnerships. Both emerging biotech firms and global pharmaceutical leaders are increasingly turning to CMOs to achieve greater operational agility and capital efficiency. The COVID-19 pandemic further highlighted the importance of resilient, high-capacity networks, cementing CMOs as indispensable partners in global healthcare preparedness.

Technological advances, ranging from AI-driven process optimisation to continuous bioprocessing, are transforming efficiency and quality standards in outsourced production. At the same time, emerging markets such as India and China are becoming more integral to global supply chains, supported by cost competitiveness and improving regulatory frameworks. These dynamics are expanding the geographic footprint of contract manufacturing, diversifying risk, and opening new avenues for growth.

As demand for biologics and next-generation therapies accelerates, contract manufacturing will remain a cornerstone of the biopharmaceutical value chain. CMOs are evolving from capacity providers into strategic partners, offering innovation, resilience, and flexibility that are increasingly essential in a competitive and fast-changing global healthcare landscape.

What would be the Impact of US Trade Tariffs on the Global Biopharmaceuticals Contract Manufacturing Market?

The introduction of U.S. trade tariffs on pharmaceutical inputs, biologics, and specialised manufacturing equipment is creating new pressures for the global biopharmaceutical contract manufacturing market. By raising the cost of raw materials, reagents, and critical production tools, these measures are disrupting established cost structures and supply chains. Contract manufacturers that rely on cross-border sourcing or export to the United States are particularly exposed, facing higher operating costs, potential delays, and reduced margins—factors that could translate into increased pricing for sponsors and limit the affordability of biologics and biosimilars.

At the same time, tariffs are prompting a reassessment of global outsourcing strategies. Biopharmaceutical companies are moving to diversify suppliers, invest in localised production capacity, and channel outsourcing toward regions unaffected by tariffs. This shift is increasing interest in Southeast Asia, India, and selected European markets, where improving regulatory standards and competitive cost bases support expansion. While U.S.-based CMOs may benefit in the short term from stronger domestic demand, their ability to maintain this position will depend on policy clarity and the scale of infrastructure investment.

In effect, tariffs are acting as both a disruptor and a catalyst—raising immediate costs while driving structural changes in how and where manufacturing is conducted. For CMOs and their partners, the priority will be to adapt quickly, balancing short-term challenges with the longer-term opportunity to build more resilient and regionally diversified supply networks.

What Questions Should You Ask before Buying a Market Research Report?

How is the biopharmaceuticals contract manufacturing market evolving?
What is driving and restraining the biopharmaceuticals contract manufacturing market?
How will each biopharmaceuticals contract manufacturing submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
How will the market shares for each biopharmaceuticals contract manufacturing submarket develop from 2025 to 2035?
What will be the main driver for the overall market from 2025 to 2035?
Will leading biopharmaceuticals contract manufacturing markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
Who are the leading players and what are their prospects over the forecast period?
What are the biopharmaceuticals contract manufacturing projects for these leading companies?
How will the industry evolve during the period between 2025 and 2035? What are the implications of
biopharmaceuticals contract manufacturing projects taking place now and over the next 10 years?
Is there a greater need for product commercialisation to further scale the biopharmaceuticals contract manufacturing market?
Where is the biopharmaceuticals contract manufacturing market heading and how can you ensure you are at the forefront of the market?
What are the best investment options for new product and service lines?
What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Biopharmaceuticals Contract Manufacturing market today, and over the next 10 years:

Our 393-page report provides 138 tables and 174 charts/graphs exclusively to you.
The report highlights key lucrative areas in the industry so you can target them – NOW.
It contains in-depth analysis of global, regional and national sales and growth.
It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2035 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2035, our new study provides you with recent results, growth rates, and market shares.
You will find original analyses, with business outlooks and developments.
Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.

Segments Covered in the Report

Source

Mammalian
Non-mammalian

Service

Process Development
– Downstream
– Upstream
Fill & Finish Operations
Analytical & QC Studies
Packaging

Product

Biologics
– Monoclonal Antibodies (mAbs)
– Recombinant Proteins
– Vaccines
– Others
Biosimilars

Company Size

Small
Mid-sized
Large

Scale of Operations

Preclinical
Clinical
Commercial

Therapeutic Area

Oncology
Autoimmune Diseases
Cardiovascular Diseases
Metabolic Diseases
Infectious Diseases
Neurology
Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 26 leading national markets:

North America

U.S.
Canada

Europe

Germany
UK
France
Italy
Spain
Rest of Europe

Asia Pacific

Japan
China
India
Australia
South Korea
Rest of Asia Pacific

Latin America

Brazil
Mexico
Rest of Latin America

MEA

GCC
South Africa
Rest of MEA

Biopharmaceuticals Contract Manufacturing Market Report 2025-2035

The report also includes profiles for some of the leading companies in the Biopharmaceuticals Contract Manufacturing Market, 2025 to 2035, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth

AbbVie Inc.
AGC Biologics
Avantor, Inc.
Binex Co., Ltd.
Boehringer Ingelheim International GmbH
Cambrex Corporation
Catalent, Inc
Curia Global, Inc.
Cytiva
FUJIFILM Diosynth Biotechnologies
JRS PHARMA
Jubilant Pharma Limited
KBI Biopharma
Lonza
Pfizer CentreOne
ProBioGen AG
Rentschler Biopharma SE
Samsung Biologics
Sandoz Group AG
TOYOBO CO., LTD.
Thermo Fisher Scientific Inc.
WuXi Biologics

Overall world revenue for Biopharmaceuticals Contract Manufacturing Market, 2025 to 2035 in terms of value the market will surpass US$17.0 billion in 2025, our work calculates. We predict strong revenue growth through to 2035. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Biopharmaceuticals Contract Manufacturing Market, 2025 to 2035 report help you?

In summary, our 390+ page report provides you with the following knowledge:

Revenue forecasts to 2035 for Biopharmaceuticals Contract Manufacturing Market 2025 to 2035, with forecasts for source, service, product, company size, and scale of operations, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
Revenue forecasts to 2035 for five regional and 26 key national markets – See forecasts for the Biopharmaceuticals Contract Manufacturing Market, 2025 to 2035 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
Prospects for established firms and those seeking to enter the market – including company profiles for 22 of the major companies involved in the Biopharmaceuticals Contract Manufacturing Market, 2025 to 2035.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

ページTOPに戻る

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Biopharmaceuticals Contract Manufacturing Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 Rise in Investment by CMOs for Capacity Expansion
3.3.1.2 Cost and Time Saving Benefits Offered by Contract Services
3.3.1.3 Outsourcing Boosting the Market Growth
3.3.1.4 Growing Investments in Orphan Drugs
3.3.2 Market Restraining Factors
3.3.2.1 Pricing Pressure to Impede Market Growth
3.3.2.2 Stringent Regulatory Scenarios
3.3.2.3 Overcapacity Projected to Challenge Market Growth
3.3.3 Market Opportunities
3.3.3.1 Expansion of Fill and Finish CMOs
3.3.3.2 Emergence of Single-Use Bioprocessing Equipment & Solutions
3.3.3.3 Emerging Economies to Offer Lucrative Growth Opportunities
3.4 U.S. Tariffs: What’s the Impact on Global Biopharmaceuticals Contract Manufacturing Market?
3.4.1 Overview
3.4.2 V-Shaped Recovery Scenario
3.4.3 Why V-Shaped Recovery?
3.4.3.1 Impact from Tariffs
3.4.3.2 Market Dynamics and Demand Recovery
3.4.3.3 Policy and Funding Support
3.4.3.4 Timeframe for Recovery
3.4.4 U-Shaped Recovery Scenario
3.4.4.1 Why U-Shaped Recovery?
3.4.4.2 Impact from Tariffs
3.4.4.3 Market Dynamics and Demand Recovery
3.4.4.4 Policy and Funding Support
3.4.4.5 Timeframe for Recovery
3.4.5 L Shaped Recovery Scenario
3.4.5.1 Why L-Shaped Recovery?
3.4.5.2 Impact from Tariffs
3.4.5.3 Market Dynamics and Demand Recovery
3.4.5.4 Policy and Funding Support
3.4.5.5 Timeframe for Recovery
3.4.6 What Strategic Considerations Should Clients Factor into Their Near-term (2025–2030) and Long-term (2025–2035) Planning?
3.4.7 Impact of U.S. and China Trade War on Biopharmaceuticals Contract Manufacturing Market
3.4.8 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
3.5 Porter’s Five Forces Analysis
3.5.1 Bargaining Power of Buyers
3.5.2 Bargaining Power of Suppliers
3.5.3 Competitive Rivalry
3.5.4 Threat of Substitutes
3.5.5 Threat of New Entrants
3.6 PEST Analysis
3.6.1 Political Factors Impacting Biopharmaceuticals Contract Manufacturing Market
3.6.2 Economic Factors Impacting Biopharmaceuticals Contract Manufacturing Market
3.6.3 Social Factors Impacting Biopharmaceuticals Contract Manufacturing Market
3.6.4 Technological Factors Impacting Biopharmaceuticals Contract Manufacturing Market

4 Biopharmaceuticals Contract Manufacturing Market Analysis by Source
4.1 Key Findings
4.2 Source Segment: Market Attractiveness Index
4.3 Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Source
4.4 Mammalian
4.4.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
4.4.2 Market Share by Region, 2025 & 2035 (%)
4.5 Non-mammalian
4.5.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
4.5.2 Market Share by Region, 2025 & 2035 (%)

5 Biopharmaceuticals Contract Manufacturing Market Analysis by Service
5.1 Key Findings
5.2 Service Segment: Market Attractiveness Index
5.3 Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Service
5.4 Process Development
5.4.1 Process Development Market Size Estimation and Forecast by Type
5.4.2 Upstream Process Development
5.4.3 Downstream Process Development
5.4.4 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
5.4.5 Market Share by Region, 2025 & 2035 (%)
5.5 Fill & Finish Operations
5.5.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
5.5.2 Market Share by Region, 2025 & 2035 (%)
5.6 Analytical & QC Studies
5.6.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
5.6.2 Market Share by Region, 2025 & 2035 (%)
5.7 Packaging
5.7.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
5.7.2 Market Share by Region, 2025 & 2035 (%)

6 Biopharmaceuticals Contract Manufacturing Market Analysis by Product
6.1 Key Findings
6.2 Product Segment: Market Attractiveness Index
6.3 Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Product
6.4 Biologics
6.4.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
6.4.2 Market Share by Region, 2025 & 2035 (%)
6.4.3 Biologics Market Size Estimation and Forecast by Type
6.4.3.1 Monoclonal Antibodies (mAbs)
6.4.3.2 Recombinant Proteins
6.4.3.3 Vaccines
6.4.3.4 Others
6.5 Biosimilars
6.5.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
6.5.2 Market Share by Region, 2025 & 2035 (%)

7 Biopharmaceuticals Contract Manufacturing Market Analysis by Company Size
7.1 Key Findings
7.2 Company Size Segment: Market Attractiveness Index
7.3 Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Company Size
7.4 Small
7.4.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
7.4.2 Market Share by Region, 2025 & 2035 (%)
7.5 Mid-sized
7.5.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
7.5.2 Market Share by Region, 2025 & 2035 (%)
7.6 Large
7.6.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
7.6.2 Market Share by Region, 2025 & 2035 (%)

8 Biopharmaceuticals Contract Manufacturing Market Analysis by Scale of Operations
8.1 Key Findings
8.2 Scale of Operations Segment: Market Attractiveness Index
8.3 Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Scale of Operations
8.4 Preclinical
8.4.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
8.4.2 Market Share by Region, 2025 & 2035 (%)
8.5 Clinical
8.5.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
8.5.2 Market Share by Region, 2025 & 2035 (%)
8.6 Commercial
8.6.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
8.6.2 Market Share by Region, 2025 & 2035 (%)

9 Biopharmaceuticals Contract Manufacturing Market Analysis by Therapeutic Area
9.1 Key Findings
9.2 Therapeutic Area Segment: Market Attractiveness Index
9.3 Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Therapeutic Area
9.4 Oncology
9.4.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
9.4.2 Market Share by Region, 2025 & 2035 (%)
9.5 Autoimmune Diseases
9.5.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
9.5.2 Market Share by Region, 2025 & 2035 (%)
9.6 Cardiovascular Diseases
9.6.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
9.6.2 Market Share by Region, 2025 & 2035 (%)
9.7 Metabolic Diseases
9.7.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
9.7.2 Market Share by Region, 2025 & 2035 (%)
9.8 Infectious Diseases
9.8.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
9.8.2 Market Share by Region, 2025 & 2035 (%)
9.9 Neurology
9.9.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
9.9.2 Market Share by Region, 2025 & 2035 (%)
9.10 Others
9.10.1 Market Forecast by Region, 2025-2035 (US$ Million, AGR %)
9.10.2 Market Share by Region, 2025 & 2035 (%)

10 Biopharmaceuticals Contract Manufacturing Market Analysis by Region
10.1 Key Findings
10.2 Regional Market Size Estimation and Forecast

11 North America Biopharmaceuticals Contract Manufacturing Market Analysis
11.1 Key Findings
11.2 North America Biopharmaceuticals Contract Manufacturing Market Attractiveness Index
11.3 North America Biopharmaceuticals Contract Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Million)
11.4 North America Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Country
11.5 North America Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Source
11.6 North America Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Service
11.7 North America Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Product
11.8 North America Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Company Size
11.9 North America Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Scale of Operations
11.10 North America Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Therapeutic Area
11.11 U.S. Biopharmaceuticals Contract Manufacturing Market Analysis
11.12 Canada Biopharmaceuticals Contract Manufacturing Market Analysis

12 Europe Biopharmaceuticals Contract Manufacturing Market Analysis
12.1 Key Findings
12.2 Europe Biopharmaceuticals Contract Manufacturing Market Attractiveness Index
12.3 Europe Biopharmaceuticals Contract Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Million)
12.4 Europe Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Country
12.5 Europe Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Source
12.6 Europe Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Service
12.7 Europe Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Product
12.8 Europe Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Company Size
12.9 Europe Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Scale of Operations
12.10 Europe Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Therapeutic Area
12.11 Germany Biopharmaceuticals Contract Manufacturing Market Analysis
12.12 UK Biopharmaceuticals Contract Manufacturing Market Analysis
12.13 France Biopharmaceuticals Contract Manufacturing Market Analysis
12.14 Italy Biopharmaceuticals Contract Manufacturing Market Analysis
12.15 Spain Biopharmaceuticals Contract Manufacturing Market Analysis
12.16 Russia Biopharmaceuticals Contract Manufacturing Market Analysis
12.17 Netherlands Biopharmaceuticals Contract Manufacturing Market Analysis
12.18 Switzerland Biopharmaceuticals Contract Manufacturing Market Analysis
12.19 Rest of Europe Biopharmaceuticals Contract Manufacturing Market Analysis

13 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Analysis
13.1 Key Findings
13.2 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Attractiveness Index
13.3 Asia Pacific Biopharmaceuticals Contract Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Million)
13.4 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Country
13.5 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Source
13.6 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Service
13.7 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Product
13.8 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Company Size
13.9 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Scale of Operations
13.10 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Therapeutic Area
13.11 Japan Biopharmaceuticals Contract Manufacturing Market Analysis
13.12 China Biopharmaceuticals Contract Manufacturing Market Analysis
13.13 India Biopharmaceuticals Contract Manufacturing Market Analysis
13.14 Australia Biopharmaceuticals Contract Manufacturing Market Analysis
13.15 South Korea Biopharmaceuticals Contract Manufacturing Market Analysis
13.16 South-East Asia Biopharmaceuticals Contract Manufacturing Market Analysis
13.17 Rest of Asia Pacific Biopharmaceuticals Contract Manufacturing Market Analysis

14 Latin America Biopharmaceuticals Contract Manufacturing Market Analysis
14.1 Key Findings
14.2 Latin America Biopharmaceuticals Contract Manufacturing Market Attractiveness Index
14.3 Latin America Biopharmaceuticals Contract Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Million)
14.4 Latin America Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Country
14.5 Latin America Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Source
14.6 Latin America Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Service
14.7 Latin America Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Product
14.8 Latin America Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Company Size
14.9 Latin America Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Scale of Operations
14.10 Latin America Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Therapeutic Area
14.11 Brazil Biopharmaceuticals Contract Manufacturing Market Analysis
14.12 Mexico Biopharmaceuticals Contract Manufacturing Market Analysis
14.13 Argentina Biopharmaceuticals Contract Manufacturing Market Analysis
14.14 Colombia Biopharmaceuticals Contract Manufacturing Market Analysis
14.15 Rest of Latin America Biopharmaceuticals Contract Manufacturing Market Analysis

15 MEA Biopharmaceuticals Contract Manufacturing Market Analysis
15.1 Key Findings
15.2 MEA Biopharmaceuticals Contract Manufacturing Market Attractiveness Index
15.3 MEA Biopharmaceuticals Contract Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Million)
15.4 MEA Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Country
15.5 MEA Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Source
15.6 MEA Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Service
15.7 MEA Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Product
15.8 MEA Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Company Size
15.9 MEA Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Scale of Operations
15.10 MEA Biopharmaceuticals Contract Manufacturing Market Size Estimation and Forecast by Therapeutic Area
15.11 GCC Biopharmaceuticals Contract Manufacturing Market Analysis
15.12 South Africa Biopharmaceuticals Contract Manufacturing Market Analysis
15.13 Rest of MEA Biopharmaceuticals Contract Manufacturing Market Analysis

16 Company Profiles
16.1 AbbVie, Inc.
16.1.1 Company Snapshot
16.1.2 Company Overview
16.1.3 Financial Analysis
16.1.3.1 Net Revenue, 2020-2024
16.1.3.2 R&D Expenses, 2020-2024
16.1.3.3 Regional Market Shares, 2024
16.1.3.4 Business Segment Market Shares, 2024
16.1.4 Service Benchmarking
16.2 AGC Biologics
16.2.1 Company Snapshot
16.2.2 Company Overview
16.2.3 Service Benchmarking
16.2.4 Strategic Outlook
16.3 Avantor, Inc.
16.3.1 Company Snapshot
16.3.2 Company Overview
16.3.3 Financial Analysis
16.3.3.1 Net Revenue, 2020-2024
16.3.3.2 Business Segment Market Shares, 2024
16.3.4 Service Benchmarking
16.3.5 Strategic Outlook
16.4 Binex Co., Ltd.
16.4.1 Company Snapshot
16.4.2 Company Overview
16.4.3 Service Benchmarking
16.5 Boehringer Ingelheim GmbH
16.5.1 Company Snapshot
16.5.2 Company Overview
16.5.3 Financial Analysis
16.5.3.1 Net Revenue, 2020-2024
16.5.4 Service Benchmarking
16.6 FUJIFILM Diosynth Biotechnologies
16.6.1 Company Snapshot
16.6.2 Company Overview
16.6.3 Service Benchmarking
16.6.4 Strategic Outlook
16.7 Lonza
16.7.1 Company Snapshot
16.7.2 Company Overview
16.7.3 Financial Analysis
16.7.3.1 Net Revenue, 2020-2024
16.7.3.2 R&D Expenses, 2018-2022
16.7.4 Service Benchmarking
16.7.5 Strategic Outlook
16.8 ProBioGen
16.8.1 Company Snapshot
16.8.2 Company Overview
16.8.3 Service Benchmarking
16.8.4 Strategic Outlook
16.9 Rentschler Biopharma SE
16.9.1 Company Snapshot
16.9.2 Company Overview
16.9.3 Service Benchmarking
16.9.4 Strategic Outlook
16.10 Samsung Biologics
16.10.1 Company Snapshot
16.10.2 Company Overview
16.10.3 Service Benchmarking
16.10.4 Strategic Outlook
16.11 Sandoz
16.11.1 Company Snapshot
16.11.2 Company Overview
16.11.3 Financial Analysis
16.11.3.1 Net Revenue, 2020-2024
16.11.3.2 Regional Market Shares, 2024
16.11.4 Service Benchmarking
16.11.5 Strategic Outlook
16.12 TOYOBO CO., LTD.
16.12.1 Company Snapshot
16.12.2 Company Overview
16.12.3 Service Benchmarking
16.13 WuXi Biologics
16.13.1 Company Snapshot
16.13.2 Company Overview
16.13.3 Financial Analysis
16.13.3.1 Net Revenue, 2020-2024
16.13.3.2 Regional Market Shares, 2024
16.13.3.3 Business Segment Market Shares, 2024
16.13.4 Service Benchmarking
16.13.5 Strategic Outlook
16.14 JRS PHARMA
16.14.1 Company Snapshot
16.14.2 Company Overview
16.14.3 Service Benchmarking
16.15 Thermo Fisher Scientific
16.15.1 Company Snapshot
16.15.2 Company Overview
16.15.3 Financial Analysis
16.15.3.1 Net Revenue, 2020-2024
16.15.3.2 R&D, 2020-2024
16.15.3.3 Regional Market Shares, 2024
16.15.3.4 Business Segment Market Shares, 2024
16.15.4 Service Benchmarking
16.16 Cambrex Corporation
16.16.1 Company Snapshot
16.16.2 Company Overview
16.16.3 Service Benchmarking
16.16.4 Strategic Outlook
16.17 Curia Global, Inc.
16.17.1 Company Snapshot
16.17.2 Company Overview
16.17.3 Service Benchmarking
16.17.4 Strategic Outlook
16.18 Pfizer CentreOne
16.18.1 Company Snapshot
16.18.2 Company Overview
16.18.3 Financial Analysis
16.18.3.1 Net Revenue, 2020-2024
16.18.3.2 R&D, 2020-2024
16.18.3.3 Regional Market Shares, 2024
16.18.3.4 Business Segment Market Shares, 2024
16.18.4 Service Benchmarking
16.19 Jubilant Pharma Limited
16.19.1 Company Snapshot
16.19.2 Company Overview
16.19.3 Service Benchmarking
16.20 Catalent, Inc. (Novo Holdings)
16.20.1 Company Snapshot
16.20.2 Company Overview
16.20.3 Financial Analysis
16.20.3.1 Net Revenue, 2020-2024
16.20.4 Service Benchmarking
16.20.5 Strategic Outlook
16.21 KBI Biopharma
16.21.1 Company Snapshot
16.21.2 Company Overview
16.21.3 Service Benchmarking
16.21.4 Strategic Outlook
16.22 Cytiva
16.22.1 Company Snapshot
16.22.2 Company Overview
16.22.3 Service Benchmarking
16.22.4 Strategic Outlook

17 Conclusion and Recommendations
17.1 Concluding Remarks from Visiongain
17.2 Recommendations for Market Players

ページTOPに戻る

List of Tables/Graphs

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

Visiongain社のヘルスケアと医薬・化学品分野での最新刊レポート

本レポートと同じKEY WORD（biopharmaceuticals）の最新刊レポート

よくあるご質問

Visiongain社はどのような調査会社ですか?

英国の調査会社ヴィジョンゲイン社（Visiongain）は、通信とエネルギーのほか、自動車や化学・医薬品、金属など、広範な市場を対象に調査を行っています。自動車市場については、市場全般に関する調査のほ... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

バイオ医薬品受託製造市場レポート：2025-2035

サマリー

米国の貿易関税が世界のバイオ医薬品受託製造市場に与える影響とは？

市場調査レポートを購入する前にすべき質問とは？

バイオ医薬品受託製造市場が現在、そして今後10年間でどのような影響を受けるかを知る必要がある：

2035年までの予測やその他の分析から、商業的な展望が見えてきた

レポート対象セグメント

ソース

サービス

製品

会社規模

事業規模

治療分野

北米

欧州

アジア太平洋

ラテンアメリカ

MEA

主要企業と市場成長の可能性

バイオ医薬品受託製造市場、2025-2035年レポートはどのようにお役に立ちますか？

目次

図表リスト

Summary

What would be the Impact of US Trade Tariffs on the Global Biopharmaceuticals Contract Manufacturing Market?

What Questions Should You Ask before Buying a Market Research Report?

You need to discover how this will impact the Biopharmaceuticals Contract Manufacturing market today, and over the next 10 years:

Forecasts to 2035 and other analyses reveal commercial prospects

Segments Covered in the Report

Source

Service

Product

Company Size

Scale of Operations

Therapeutic Area

North America

Europe

Asia Pacific

Latin America

MEA

Leading companies and the potential for market growth

How will the Biopharmaceuticals Contract Manufacturing Market, 2025 to 2035 report help you?

Table of Contents

List of Tables/Graphs

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（バイオ薬物）の最新刊レポート

Visiongain社の ヘルスケアと医薬・化学品分野 での最新刊レポート

本レポートと同じKEY WORD（biopharmaceuticals）の最新刊レポート

よくあるご質問

Visiongain社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?

Visiongain社のヘルスケアと医薬・化学品分野での最新刊レポート